Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis.
chemoembolization
liver cancer
radical treatment
risk factors
survival
transarterial
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
08 Mar 2022
08 Mar 2022
Historique:
received:
31
01
2022
revised:
03
03
2022
accepted:
07
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Chemolipiodolization (CL) is less invasive than transarterial chemoembolization (TACE) for managing hepatocellular carcinoma (HCC) because it helps avoid embolization. However, the treatment outcomes of percutaneous radiofrequency ablation (PRFA) with or without CL for HCC remain unclear. Herein, we compared the prognostic factors for overall survival (OS) following PRFA with or without CL for HCC using propensity-score-matched analysis. A total of 221 patients with HCC treated with PRFA at Saga Central Hospital between April 2004 and October 2020, with or without CL, were enrolled. No significant difference was observed in OS between PRFA with and without CL cohorts (median survival time (MST): 4.5 vs. 5.4 years;
Identifiants
pubmed: 35329809
pii: jcm11061483
doi: 10.3390/jcm11061483
pmc: PMC8953328
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
J Natl Cancer Inst. 2013 Jan 2;105(1):59-68
pubmed: 23150720
Semin Liver Dis. 2010 Feb;30(1):61-74
pubmed: 20175034
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Cancer. 2010 Dec 1;116(23):5452-60
pubmed: 20672352
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Nihon Rinsho. 2001 Oct;59 Suppl 6:581-5
pubmed: 11762015
Rheum Dis Clin North Am. 2018 May;44(2):203-213
pubmed: 29622292
J Hepatol. 2001 Sep;35(3):421-30
pubmed: 11592607
Stat Med. 2013 Jul 20;32(16):2837-49
pubmed: 23239115
Ann Surg Oncol. 2011 Dec;18(13):3624-31
pubmed: 21614626
World J Gastroenterol. 2015 Sep 28;21(36):10327-35
pubmed: 26420959
Oncol Lett. 2017 Sep;14(3):3199-3206
pubmed: 28927066
Ann Surg Oncol. 2011 Jun;18(6):1624-9
pubmed: 21445671
Hepatol Res. 2019 Aug;49(8):919-928
pubmed: 30969006
J Hepatol. 2020 Feb;72(2):250-261
pubmed: 31954490
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
Dig Dis Sci. 2012 May;57(5):1404-12
pubmed: 22271410
AJR Am J Roentgenol. 2010 Mar;194(3):830-7
pubmed: 20173167
Korean J Intern Med. 2016 Mar;31(2):242-52
pubmed: 26874512
J Vasc Interv Radiol. 2019 Oct;30(10):1533-1543
pubmed: 31471190
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Radiology. 2000 Oct;217(1):119-26
pubmed: 11012432
Radiology. 2013 Dec;269(3):927-37
pubmed: 24086071
Semin Diagn Pathol. 2017 Mar;34(2):153-159
pubmed: 28108047
Oncotarget. 2016 May 24;7(21):31311-21
pubmed: 27121318
Radiology. 2002 Jul;224(1):47-54
pubmed: 12091661
J Hepatol. 2009 Dec;51(6):1030-6
pubmed: 19864035
J Clin Oncol. 2013 Feb 1;31(4):426-32
pubmed: 23269991
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Oncotarget. 2017 Jan 10;8(2):2960-2970
pubmed: 27936465
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593